CareDx Raises 2026 Revenue Outlook After Strong Second Quarter

CareDx (NASDAQ: CDNA) raised its 2026 revenue guidance after reporting second-quarter results that exceeded expectations, driven by continued growth in its transplant diagnostics business and recent expansion into oncology.

Revenue increased 52% year over year to $132 million, led by a 61% increase in testing services revenue to $100 million on approximately 58,000 tests performed during the quarter. The company also reported adjusted EBITDA of $25 million and increased its full-year revenue outlook to $490 million-$500 million, up from $447 million-$465 million previously.

During the quarter, CareDx completed its acquisition of Naveris, adding the NavDx blood test for HPV-associated cancers and expanding its precision diagnostics portfolio beyond transplant monitoring. The company also benefited from a finalized Medicare coverage policy supporting reimbursement for its core AlloSure and AlloMap transplant surveillance tests.

H.C. Wainwright reiterated its Neutral rating and $46 price target, citing stronger revenue momentum while maintaining a balanced valuation outlook.